Xenon Pharmaceuticals Inc.
XENE
$34.70
-$0.41-1.17%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | 44.79% | 32.86% | 12.86% | 11.98% | 17.93% |
| Gross Profit | -44.79% | -32.86% | -12.86% | -11.98% | -17.93% |
| SG&A Expenses | 42.68% | 30.47% | 67.49% | 55.12% | 48.44% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 44.29% | 32.31% | 24.23% | 20.37% | 23.92% |
| Operating Income | -44.29% | -32.31% | -24.23% | -20.37% | -23.92% |
| Income Before Tax | -54.70% | -29.81% | -22.18% | -14.68% | -23.97% |
| Income Tax Expenses | -1,777.07% | -103.82% | -51.36% | 42.07% | -118.00% |
| Earnings from Continuing Operations | -46.81% | -29.57% | -22.05% | -14.87% | -19.65% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -46.81% | -29.57% | -22.05% | -14.87% | -19.65% |
| EBIT | -44.29% | -32.31% | -24.23% | -20.37% | -23.92% |
| EBITDA | -45.42% | -35.32% | -24.40% | -20.01% | -23.42% |
| EPS Basic | -31.04% | -9.75% | -3.50% | 2.71% | -12.33% |
| Normalized Basic EPS | -37.64% | -8.86% | -1.41% | 7.06% | -10.57% |
| EPS Diluted | -31.04% | -9.75% | -3.50% | 2.71% | -12.33% |
| Normalized Diluted EPS | -37.64% | -8.86% | -1.41% | 7.06% | -10.57% |
| Average Basic Shares Outstanding | 12.03% | 18.07% | 17.93% | 18.06% | 6.56% |
| Average Diluted Shares Outstanding | 12.03% | 18.07% | 17.93% | 18.06% | 6.56% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |